Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

History of passive antibody administration for prevention and treatment of infectious diseases

History of passive antibody administration for prevention and treatment of infectious diseases REVIEW URRENT History of passive antibody administration for PINION prevention and treatment of infectious diseases a b Barney S. Graham and Donna M. Ambrosino Purpose of review We describe the history of passive immunization to provide context for the series of articles to follow. The history of passive immunization with antibodies to prevent or treat infectious diseases is a story of different eras. There was an extraordinary era of discovery and clinical implementation before the chemical nature of antibodies was even known. This empirical process provided the resources and reagents used to describe and characterize humoral immunity, better define the chemical properties and structure of antibodies, and extend the clinical use of immunoglobulin products to treat or prevent multiple viral and bacterial diseases over the ensuing several decades. The next distinct era came with the discovery of processes to produce monoclonal antibodies (mAbs), and development of more specific therapies. Interestingly, mAb technology resulted in many products to treat autoimmune and allergic diseases, but only one common infectious disease, respiratory syncytial virus, and only in a restricted population of high- risk infants. Recent findings The current era began in 2003 with a series of publications demonstrating processes for rapidly producing http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and Aids Wolters Kluwer Health

History of passive antibody administration for prevention and treatment of infectious diseases

Current Opinion in HIV and Aids , Volume 10 (3) – May 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/history-of-passive-antibody-administration-for-prevention-and-36OHyeSfu7

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000154
pmid
25760933
Publisher site
See Article on Publisher Site

Abstract

REVIEW URRENT History of passive antibody administration for PINION prevention and treatment of infectious diseases a b Barney S. Graham and Donna M. Ambrosino Purpose of review We describe the history of passive immunization to provide context for the series of articles to follow. The history of passive immunization with antibodies to prevent or treat infectious diseases is a story of different eras. There was an extraordinary era of discovery and clinical implementation before the chemical nature of antibodies was even known. This empirical process provided the resources and reagents used to describe and characterize humoral immunity, better define the chemical properties and structure of antibodies, and extend the clinical use of immunoglobulin products to treat or prevent multiple viral and bacterial diseases over the ensuing several decades. The next distinct era came with the discovery of processes to produce monoclonal antibodies (mAbs), and development of more specific therapies. Interestingly, mAb technology resulted in many products to treat autoimmune and allergic diseases, but only one common infectious disease, respiratory syncytial virus, and only in a restricted population of high- risk infants. Recent findings The current era began in 2003 with a series of publications demonstrating processes for rapidly producing

Journal

Current Opinion in HIV and AidsWolters Kluwer Health

Published: May 1, 2015

There are no references for this article.